Key Takeaways
- • OpZira, Inc., an ophthalmic medical device company focused on detecting and monitoring ocular disease, has been selected to present at the 2026 New York Venture Summit on November 18-19 at the Javits Center in New York City.
- • The summit, hosted by youngStartup Ventures, will feature 200 selected companies presenting to venture capital firms, corporate investors, angel investors, and industry leaders.
- • OpZira will showcase its ophthalmic portfolio, led by AdaptDx Pro, a portable dark adaptometer that objectively measures dark adaptation function, alongside its electrophysiology technologies for evaluating visual function.
- • CEO Clark Tedford, Ph.D., says the presentation is intended to introduce investors to the company's technology portfolio, commercial strategy, and plans to expand the role of advanced diagnostics in eye care.
- • Investors and strategic partners can contact [email protected] to arrange meetings.
Summary
OpZira, Inc., an ophthalmic medical device company based in Middletown, Pennsylvania, announced that it has been selected to present at the 2026 New York Venture Summit, according to a Business Wire release. The summit takes place November 18-19 at the Javits Center in New York City and is hosted by youngStartup Ventures. The event will feature 200 innovative companies presenting their technologies and growth opportunities to an audience that includes venture capital firms, corporate investors, angel investors, and industry leaders.
At the summit, OpZira will showcase its portfolio of ophthalmic technologies. The centerpiece is AdaptDx Pro, a portable dark adaptometer that objectively measures dark adaptation function. The company will also present its electrophysiology technologies used to evaluate visual function. The company says it is focused on expanding access to advanced technologies that support clinical decision-making and patient care.
Company President and CEO Clark Tedford, Ph.D., said OpZira is "uniquely positioned to build on a portfolio of established ophthalmic technologies with a clear strategy for future growth." He described the selection as an opportunity to introduce investors to the company's technology portfolio, commercial strategy, and vision for expanding the role of advanced diagnostics in eye care.
The release notes that OpZira's creation follows Alcon's acquisition of LumiThera and its Valeda Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration. Investors and strategic partners interested in meeting with OpZira during the summit may contact [email protected].
At the summit, OpZira will showcase its portfolio of ophthalmic technologies. The centerpiece is AdaptDx Pro, a portable dark adaptometer that objectively measures dark adaptation function. The company will also present its electrophysiology technologies used to evaluate visual function. The company says it is focused on expanding access to advanced technologies that support clinical decision-making and patient care.
Company President and CEO Clark Tedford, Ph.D., said OpZira is "uniquely positioned to build on a portfolio of established ophthalmic technologies with a clear strategy for future growth." He described the selection as an opportunity to introduce investors to the company's technology portfolio, commercial strategy, and vision for expanding the role of advanced diagnostics in eye care.
The release notes that OpZira's creation follows Alcon's acquisition of LumiThera and its Valeda Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration. Investors and strategic partners interested in meeting with OpZira during the summit may contact [email protected].
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.